Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific ReportsBusiness Wire • 06/14/22
Oragenics Extends Collaboration to Develop Vaccines against Future Variants of CoronavirusesBusiness Wire • 04/06/22
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1Business Wire • 03/22/22
Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1Business Wire • 03/10/22
Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint ManuscriptBusiness Wire • 03/03/22
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of QuorumBusiness Wire • 01/26/22
OGEN Stock Alert: The Insider Buying Giving Oragenics Shares Some Oomph TodayInvestorPlace • 01/04/22
Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron VariantBusiness Wire • 12/20/21
Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global PartnersBusiness Wire • 12/09/21
Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of LantibioticsBusiness Wire • 12/08/21
Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine CandidateBusiness Wire • 12/01/21
Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.Business Wire • 10/04/21
